Pluri Inc
NASDAQ:PLUR

Watchlist Manager
Pluri Inc Logo
Pluri Inc
NASDAQ:PLUR
Watchlist
Price: 4.58 USD -4.98% Market Closed
Market Cap: 25.5m USD
Have any thoughts about
Pluri Inc?
Write Note

Operating Margin
Pluri Inc

-3 675.4%
Current
-9 236%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 675.4%
=
Operating Profit
-22m
/
Revenue
598k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IL
Pluri Inc
NASDAQ:PLUR
25.2m USD
-3 675%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country IL
Market Cap 25.2m USD
Operating Margin
-3 675%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 315.2B USD
Operating Margin
28%
Country US
Market Cap 141.9B USD
Operating Margin
19%
Country US
Market Cap 116.4B USD
Operating Margin
38%
Country US
Market Cap 104.5B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 78.7B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Pluri Inc
Glance View

Market Cap
25.2m USD
Industry
Biotechnology

Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

PLUR Intrinsic Value
1.42 USD
Overvaluation 69%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 675.4%
=
Operating Profit
-22m
/
Revenue
598k
What is the Operating Margin of Pluri Inc?

Based on Pluri Inc's most recent financial statements, the company has Operating Margin of -3 675.4%.